The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study.
 
Orazio Caffo
Consulting or Advisory Role - Astellas Pharma
 
Ugo De Giorgi
Honoraria - Janssen
 
Gaetano Facchini
No Relationships to Disclose
 
Lucia Fratino
No Relationships to Disclose
 
Donatello Gasparro
No Relationships to Disclose
 
Umberto Basso
No Relationships to Disclose
 
Daniele Alesini
No Relationships to Disclose
 
Marcello Tucci
No Relationships to Disclose
 
Cinzia Ortega
Honoraria - Astellas Pharma; Bayer
 
Francesco Verderame
No Relationships to Disclose
 
Giuseppe Procopio
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Novartis
 
Giovanni Lo Re
No Relationships to Disclose
 
Enrico Campadelli
No Relationships to Disclose
 
Claudia Omarini
No Relationships to Disclose
 
Maddalena Donini
No Relationships to Disclose
 
Franco Morelli
No Relationships to Disclose
 
Paolo A. Zucali
No Relationships to Disclose
 
Donata Sartori
No Relationships to Disclose
 
Vincenza Conteduca
No Relationships to Disclose
 
Enzo Galligioni
No Relationships to Disclose